KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Non-Current Liabilities (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 12.82% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Dec 2025, up 12.82%, and an annual FY2025 reading of $1.4 billion, up 12.82% over the prior year.
  • Total Non-Current Liabilities was $1.4 billion for Q4 2025 at Biomarin Pharmaceutical, down from $1.4 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.8 billion in Q4 2023 and bottomed at $1.2 billion in Q4 2024.
  • Average Total Non-Current Liabilities over 5 years is $1.5 billion, with a median of $1.6 billion recorded in 2021.
  • The sharpest move saw Total Non-Current Liabilities crashed 32.09% in 2024, then increased 12.82% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $1.6 billion in 2021, then grew by 1.9% to $1.7 billion in 2022, then grew by 5.87% to $1.8 billion in 2023, then plummeted by 32.09% to $1.2 billion in 2024, then rose by 12.82% to $1.4 billion in 2025.
  • Business Quant data shows Total Non-Current Liabilities for BMRN at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.3 billion in Q2 2025.